The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
GlobalData on MSN
Edwards solidifies TAVR dominance in long-term trial readout
The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.
Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback